Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme v. TKT Patent Appeal Is Second Front In Orphan Exclusivity Battle

Executive Summary

An appeals court decision in the Genzyme v. Transkaryotic Therapies patent case could have implications for the marketing of the companies' Fabry disease products in the U.S. and Europe

You may also be interested in...

TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model

Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions

Genzyme/TKT Fabry Agents Receive Co-Exclusive Orphan Drug Status In EU

Genzyme's Fabrazyme and Transkaryotic Therapies' Replagal will split the 5,000-patient Fabry's disease market in Europe following the awarding of co-exclusive orphan status by the European Commission.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts